p53 Unleashes Endogenous Retroviruses to Tackle Tumors: Study

New experiments suggest the famous tumor-suppressing protein uses viral elements lingering in the genome to get cancerous cells to announce their presence to the immune system.

Written byMarcus A. Banks
| 4 min read
visualization of p53 protein interacting with its inhibitors MDM2 and MDMX

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

ABOVE: When MDM2 (violet) and MDMX (red) are prevented from messing with p53 (blue), the famous tumor-surpressing protein lets endogenous retroviruses loose, ultimately helping the immune system spot cancerous cells.
© ISTOCK.COM, SELVANEGRA

The tumor suppressing protein p53 has earned the nickname “guardian of the genome” because of its well-studied arsenal of techniques for responding to genetic damage. When it binds to damaged DNA, it can activate DNA repair proteins, pause the cell division process until repairs are complete, or trigger programmed cell death if the damage is irreversible. Now, new research suggests p53 has another trick up its sleeve: it can force cancer cells out of hiding by making them go viral.

Often, tumors persist in the body because “cancer cells are hiding from immune cells,” says Galina Selivanova, a tumor biologist at the Karolinska Institutet in Sweden. She’s the lead author on the new study, published July 6 in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • marcus a. banks

    Marcus is a science and health journalist based in New York City. He graduated from the Science Health and Environmental Reporting Program at New York University in 2019, and earned a master’s in Library and Information Science from Dominican University in 2002. He’s written for Slate, Undark, Spectrum, and Cancer Today.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies